Abstract
In renal graft recipients primarily treated with cyclosporin and low-dose methylprednisolone, withdrawal of the long-term steroid medication increases the likelihood of developing rejection episodes. In order to determine the predictive value of clinical parameters and routine prewithdrawal graft biopsies for the risk of rejection, the authors studied 141 kidney recipients from whom steroids were with-drawn 7–9 months after transplantation in a clinically stable situation. Both the quality of the HLA-match and the results of prospective graft biopsies were found to correlate significantly to the occurrence of acute rejection. In order to investigate the influence of additional azathioprine medication on the incidence of acute rejections in recipients not receiving steroids, immunosuppression was continued with cyclosporin monotherapy in 88 patients and with cyclosporin plus azathioprine in 53 patients. The risk of developing rejection episodes was significantly reduced from 48% after 1 year on monotherapy to 28% after the addition of azathioprine medication.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Canadian Multicentre Transplant Study Group (1986) A randomized clinical trial of cyclosporin in cadaveric renal transplantation: analysis at three years. N Engl J Med 314: 1219–1225
Canafax DM, Martel EJ, Ascher NL, Payne WP, Sutherland DER, Simmons RL, Najarian JS (1985) Two methods of managing cyclosporine nephrotoxicity. Conversion to azathioprine, prednisone, or cyclosporine, azathioprine, and prednisone. Transplant Proc 17: 1176–1178
Christinelli L, Brunori G, Setti G, Manganoni A, Manfanoni AM, Scolari F, Sandrini S, Scaini PS, Savoldi S, Camerini C, Maiorca R (1987) Withdrawal of methylprednisolone at the sixth month in renal transplant recipients treated with cyclosporine. Transplant Proc 19: 2021–2023
Flechner SM, Buren CT van, Jarowenko M, Kerman R, Kahan BD (1985) The fate of patients converted from cyclosporine to azathioprine to improve renal function. Transplant Proc 17: 1227–1230
Gianello P, Squifflet JP, Prison Y, Stoffel M, Dereme T, Alexandre GPJ (1987) Cyclosporine-steroids versus conventional therapy in cadaver kidney transplantation. Transplant Proc 19: 1867–1872
Hall BM, Tiller DJ, Hardie I, Mahony J, Mathew T, Thatcher G, Miach P, Thomson N, Sheil AGR (1988) Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 318: 1499–1507
Kahan BD, Mickey R, Flechner SM, Lorber M, Wideman CA, Kerman RH, Terasaki P, Buren CT van (1987) Risk factors for cadaveric donor allograft survival in cyclosporine-prednisone-treated recipients. Transplant Proc 19: 1835–1839
Kupin W, Venkat KK, Florence-Green D, Norris C, Oh KK, Dienst S, Levin NW (1987) Corticosteroid withdrawal with substitution of azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplant Proc 19: 2024–2026
Lloveras J, Masramon J, Orfila A, Cuevas X, Aubia J (1987) Stopping prednisone in kidney transplant recipients taking cyclosporine: safety conditions. Transplant Proc 19: 2027–2028
Morris PJ, French ME, Dunnil MJ, Hunnisett AGW, Ting A, Thompson JF, Wood RFM (1983) A controlled trial of cyclosporin in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 36: 273–277
Offermann G (1988) HLA-based local donor/recipient matching in renal transplantation. Int J Biomed Comput 22: 251–257
Opelz G (1985) Effect of HLA matching, blood transfusions, and presensitization in cyclosporine-treated kidney transplant recipients. Transplant Proc 17: 2179–2183
Opelz G for the Collaborative Transplant Study (1988) The benefit of exchanging donor kidneys among transplant centers. N Engl J Med 318: 1289–1292
Peto R, Pike MC, Armitage P, Brescow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39
Rocher LL, Milford EL, Kirkman RL, Carpenter CB, Strom TB, Tilney NL (1984) Conversion from cyclosporine to azathioprine in renal allograft recipients. Transplantation 38: 669–674
Rood JJ van (1987) Prospective HLA typing is helpful in cadaveric renal transplantation. Transplant Proc 19: 139–143
Shen SY, Zemel SM, Weir MR, Dagher FJ, Bentley FR (1987) Conversion of cyclosporine to azathioprine in renal transplant patients. Transplant Proc 19: 2032–2036
Weimar W, Versluis DJ, Wenting GJ, Derkx FHM, Schalekamp MADH, Jeekel J (1987) Prolonged cyclosporine therapy to induce solid engraftment after renal transplantation. Transplant Proc 19: 1998–1999
Zemel SM, Shen SY, Weir MR, Dagher FJ, Bentley FR (1987) Effects of HLA matching and panel reactive antibodies in the development of rejection after conversion of cyclosporine to azathioprine. Transplant Proc 19: 2029–2031
Author information
Authors and Affiliations
About this article
Cite this article
Offermann, G., Krause, P.H., Johann, D. et al. Late conversion from steroids to azathioprine in cyclosporin-treated renal graft recipients. Transplant Int 2, 108–112 (1989). https://doi.org/10.1007/BF02459329
Issue Date:
DOI: https://doi.org/10.1007/BF02459329